Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
Endocrinology
Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?
Related Questions
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
What is your approach in treatment of oligometastatic triple negative inflammatory breast cancer?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
What strategies do you implement to control the nausea from Enhertu?
How do you sequence therapy in metastatic ER+ HER2 low with everolimus/endocrine therapy versus fam-trastuzumab deruxtecan after progression on CDK4/6 inhibitor?
How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
When should paclitaxel (or other chemo) be discontinued in de novo metastatic triple negative breast cancer with high PDL1 in favor of continuing pembrolizumab alone with good treatment response?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
Would you consider using trastuzumab deruxtecan in a patient with progressive HR+ breast cancer that is HER2 2+ with prior history of cell cycle inhibitor related pneumonitis?
